NCT02766023: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02766023 |
|---|---|
| Title | Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 3, 2016 |
| Completion date | Feb. 11, 2019 |
| Required reporting date | Feb. 11, 2020, midnight |
| Actual reporting date | Jan. 30, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |